Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hyaluronidase 6, often referred to as HYAL6 or HYALP1, is a pseudogene within the human hyaluronidase gene family[1][3][4][5]. While the gene is transcribed, a segmental exon deletion prevents translation of a full-length, functional enzyme, leading to premature termination of the peptide[1]. As a result, HYAL6 does not produce a protein product and has no defined physiological, pathophysiological, or therapeutic relevance. The human genome contains five functional hyaluronidase genes (HYAL1–HYAL4, PH-20/SPAM1) and one pseudogene (HYAL6), all clustered on chromosomes 3 and 7[3][4][5]. HYAL6 (pseudogene) is primarily listed in genomic studies for evolutionary context and does not play a direct role in cellular processes, disease, or drug response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hyaluronidase 6 (pseudogene) (HYAL6 (occasionally HYAL6P or HYALP1)).